Key Takeaways
- A fractional CTO brings senior technology leadership to a company without the cost and commitment of a permanent C-suite technology position.
- Only 22% of surveyed life sciences leaders said their organizations had successfully scaled AI, despite 48% identifying accelerated digital transformation as a major 2026 trend.
- Mid-market biotech firms can reach a point where infrastructure, cybersecurity, data, systems integration, and AI decisions directly affect growth and operational performance.
- The strongest fractional CTO engagements connect technology decisions to business priorities rather than treating IT as a separate support function.
What Is a Fractional CTO?
A fractional CTO is an experienced technology executive who provides Chief Technology Officer-level leadership without joining a company as a full-time executive. The arrangement gives a growing organization access to strategic technology judgment when it needs it, while allowing the scope of the engagement to match its current stage, priorities, and resources.
For Atlanta biotech companies, that distinction is increasingly relevant. Gilles-André Morin (G.-A.), founder and CEO of GAMMA SOLUTIONS, notes that technology challenges often extend well beyond the IT function, requiring leadership that understands both the technical requirements and the business objectives behind them. His hands-on approach involves working directly through complex technology, operational, and organizational issues rather than limiting his role to high-level recommendations.
That perspective is particularly important for mid-market biotech firms, where technology decisions can affect research operations, data, cybersecurity, infrastructure, compliance, and the company’s ability to scale.
When Technology Becomes a Leadership Problem
A growing biotech company may initially manage technology through an internal IT lead, outside consultants, software vendors, or a combination of all three. That structure can work until technology decisions begin carrying consequences across the organization.
Consider a company preparing to expand operations. It may need to determine whether its infrastructure can support additional users, whether its systems can communicate effectively, whether data is adequately protected, and whether its technology vendors can support the next stage of growth.
Those are not simply technical questions.
They involve capital allocation, operational risk, organizational design, cybersecurity, business continuity, and long-term scalability. Someone needs to look across those areas and determine what should happen first, what can wait, and which technology investments actually support the company’s objectives.
That is fundamentally a leadership responsibility.
Why Mid-Market Biotech Firms Face a Different Technology Challenge
Large pharmaceutical companies can maintain substantial internal technology organizations covering architecture, cybersecurity, infrastructure, data, enterprise applications, and digital transformation. A mid-market biotech firm may not need — or be ready to support — that level of permanent executive infrastructure.
Yet its technology requirements can still become highly sophisticated.
Research environments generate valuable data. Commercial expansion introduces new systems. Employees and external partners need secure access. Cloud platforms become more deeply embedded in operations. Vendors multiply. Legacy systems remain in place because replacing them could disrupt critical workflows.
The result can be a technology environment where individual systems function adequately, but the overall architecture becomes difficult to manage.
A fractional CTO addresses that gap at the executive level. Rather than taking over every technical task, the role establishes priorities, evaluates risks, coordinates technology decisions, and provides leadership to the people and vendors responsible for execution.
The AI Problem Is Not Simply Choosing the Right Tool
AI makes this distinction even more important.
Life sciences organizations are investing heavily in artificial intelligence, but adoption does not automatically translate into useful business outcomes. Deloitte’s 2026 Life Sciences Outlook found that 48% of surveyed executives identified accelerated digital transformation as a trend likely to have a substantial impact on their organizations. At the same time, only 22% said their organizations had successfully scaled AI, while just 9% reported significant returns from those efforts.
That gap points to a deeper issue: technology adoption and technology execution are different problems.
A biotech company considering AI needs to ask where the technology fits into existing workflows, what data it requires, how it interacts with current systems, what governance is necessary, and how the company will determine whether the investment produced a meaningful result.
A CTO-level perspective can bring those questions together before an organization commits significant resources.
What Does a Fractional CTO Actually Do?
The work can begin with an assessment of the company’s existing technology environment.
That means examining infrastructure, applications, data flows, cybersecurity, vendors, cloud environments, internal capabilities, and technology spending. The objective is not to replace everything. It is to identify where technology is creating risk, limiting productivity, increasing costs, or preventing the business from moving forward.
From there, the fractional CTO can establish a prioritized technology roadmap.
For a growing biotech firm, that roadmap might include modernizing infrastructure, integrating disconnected systems, improving cybersecurity, evaluating technology vendors, preparing for a major transaction, supporting an executive transition, or determining whether a proposed AI initiative is technically and commercially viable.
The role can also become particularly valuable during periods of change. A company that is recruiting a permanent CTO may need interim leadership. A company preparing for a liquidity event may need technology due diligence and a clear roadmap. A company entering a new growth phase may need executive oversight before it is ready for a permanent technology organization.
Why Atlanta Biotech Firms Have a Growing Need for Technology Leadership
The broader Georgia ecosystem provides important context. The Georgia Department of Economic Development reports more than 4,000 life sciences organizations across the state, generating $27.2 billion in direct economic impact and supporting more than 78,000 jobs. Atlanta is among Georgia’s established life sciences hubs.
For mid-market companies operating in and around Atlanta, growth can therefore bring more than additional employees or facilities. It can introduce increasingly complex technology requirements across research, operations, data, cybersecurity, and commercial functions.
That does not mean every biotech company needs a CTO.
It means leadership teams should recognize when technology decisions have become too consequential to remain fragmented across individual departments, vendors, or technical specialists.
When Should a Biotech Company Bring In a Fractional CTO?
The clearest trigger is not revenue or employee count. It is technology complexity combined with business consequence.
A mid-market biotech company may be ready for fractional CTO leadership when executives are making significant technology investments without senior technology guidance, when systems no longer integrate cleanly, when cybersecurity risks are difficult to assess, or when an AI initiative is advancing without a clear implementation strategy.
The same applies during acquisitions, major infrastructure projects, executive transitions, international expansion, due diligence, or preparation for a liquidity event.
In these situations, the question is not whether the company has enough technology work to keep a full-time CTO busy. The more useful question is whether the company needs experienced executive judgment to make the technology decisions that will shape its next stage of growth.
When Technology Starts Driving Growth, Executive Leadership Has to Keep Up
A Fractional CTO is most valuable when technology has moved beyond being a support function and has become part of the company’s growth strategy.
For Atlanta’s mid-market biotech firms, that can mean bringing experienced leadership into decisions involving infrastructure, systems integration, cybersecurity, AI, vendors, and organizational priorities — at the point when those decisions begin affecting how efficiently the business can scale.
For companies at this stage, access to senior technology leadership can provide the direction needed to manage that complexity without immediately building a permanent C-suite technology structure.
GAMMA SOLUTIONS, LLC
ga.morin@gamma-solutions.llc
45 Nonantum St.
Newton
MA
02458
United States
